{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:49Z","timestamp":1789469149669,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470198"],"award-info":[{"award-number":["82470198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Innovation Project of Capital Medical University","award":["XSKY2025303"],"award-info":[{"award-number":["XSKY2025303"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07114-w","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:36:50Z","timestamp":1781224610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Central nervous system multiple myeloma: An update for 2026"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5181-6352","authenticated-orcid":false,"given":"Boyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9818-2006","authenticated-orcid":false,"given":"Wenjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-7267","authenticated-orcid":false,"given":"Menghan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5966-5523","authenticated-orcid":false,"given":"Huixing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3094-7113","authenticated-orcid":false,"given":"Songyu","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4600-099X","authenticated-orcid":false,"given":"Wen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"2","key":"7114_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11899-020-00568-3","volume":"15","author":"MH Jagosky","year":"2020","unstructured":"Jagosky MH, Usmani SZ (2020) Extramedullary Disease in Multiple Myeloma. Curr Hematol Malig R 15(2):62\u201371. https:\/\/doi.org\/10.1007\/s11899-020-00568-3","journal-title":"Curr Hematol Malig R"},{"issue":"5","key":"7114_CR2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1182\/bloodadvances.2024014345","volume":"9","author":"MR Gaballa","year":"2025","unstructured":"Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A et al (2025) BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv 9(5):1171\u20131180. https:\/\/doi.org\/10.1182\/bloodadvances.2024014345","journal-title":"Blood Adv"},{"issue":"10","key":"7114_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/ajh.27425","volume":"99","author":"E Katodritou","year":"2024","unstructured":"Katodritou E, Dalampira D, Delimpasi S, Ntanasis-Stathopoulos I, Karaolidou F et al (2024) Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group. Am J Hematol 99(10):1897\u20131905. https:\/\/doi.org\/10.1002\/ajh.27425","journal-title":"Am J Hematol"},{"issue":"3","key":"7114_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4103\/ijc.IJC_560_20","volume":"62","author":"K Jain","year":"2025","unstructured":"Jain K, Bommannan K, Ganesan P, Arumugam JR, Sagar TG et al (2025) Central nervous system involvement in multiple myeloma: Experience from a tertiary cancer center and review of literature. Indian J Cancer 62(3):416\u2013422. https:\/\/doi.org\/10.4103\/ijc.IJC_560_20","journal-title":"Indian J Cancer"},{"issue":"2","key":"7114_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/bjh.17717","volume":"195","author":"T Yamashita","year":"2021","unstructured":"Yamashita T, Takamatsu H, Kawamura K, Sunami K, Hagiwara S et al (2021) A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival. Brit J Haematol 195(2):217\u2013229. https:\/\/doi.org\/10.1111\/bjh.17717","journal-title":"Brit J Haematol"},{"issue":"2","key":"7114_CR6","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/bjh.17343","volume":"193","author":"A Claudel","year":"2021","unstructured":"Claudel A, Talbot A, Harel S, Royer B, Naelle L et al (2021) Thiotepa intrathecal injections for myelomatous central nervous system involvement. Brit J Haematol 193(2):e9\u2013e12. https:\/\/doi.org\/10.1111\/bjh.17343","journal-title":"Brit J Haematol"},{"issue":"12","key":"7114_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3760\/cma.j.issn.0253-2727.2022.12.007","volume":"43","author":"L Li","year":"2022","unstructured":"Li L, Feng ZY, Guo P, He HY, Lu J et al (2022) [A case-control study of multiple myeloma patients with central nervous system involvement]. Chinese. Chin J Hematol 43(12):1016\u20131020. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2022.12.007","journal-title":"Chin J Hematol"},{"key":"7114_CR8","doi-asserted-by":"publisher","first-page":"101343","DOI":"10.1016\/j.blre.2025.101343","volume":"74","author":"I Landry","year":"2025","unstructured":"Landry I, Binder AF, Yorker M, Ramirez S (2025) Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity. Blood Rev 74:101343. https:\/\/doi.org\/10.1016\/j.blre.2025.101343","journal-title":"Blood Rev"},{"issue":"1","key":"7114_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/joc.joc_87_24","volume":"42","author":"S De","year":"2025","unstructured":"De S, Samanta S, Shah M (2025) Plasma Cells Out for a Swim! A Study on Myelomatous Involvement of Effusion Fluid and Cerebrospinal Fluid: A 10-Year Experience from a Tertiary Cancer Center. J Cytol 42(1):48\u201353. https:\/\/doi.org\/10.4103\/joc.joc_87_24","journal-title":"J Cytol"},{"issue":"1","key":"7114_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/dc.23600","volume":"45","author":"H Ren","year":"2017","unstructured":"Ren H, Zou Y, Zhao Y, Li J, Han X et al (2017) Cerebrospinal Fluid Cytological Diagnosis in Multiple Myeloma With Leptomeningeal Involvement: A Report of Two Cases. Diagn Cytopathol 45(1):66\u201368. https:\/\/doi.org\/10.1002\/dc.23600","journal-title":"Diagn Cytopathol"},{"issue":"3","key":"7114_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3960\/jslrt.19011","volume":"59","author":"T Murase","year":"2019","unstructured":"Murase T, Inagaki A, Masaki A, Fujii K, Narita T et al (2019) Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system. J Clin Exp Hematop 59(3):135\u2013139. https:\/\/doi.org\/10.3960\/jslrt.19011","journal-title":"J Clin Exp Hematop"},{"issue":"12","key":"7114_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3941\/jrcr.v13i12.3784","volume":"13","author":"W Lee","year":"2019","unstructured":"Lee W, Chen RC, Swaminathan SK, Ho CL (2019) Extramedullary multiple myeloma with central nervous system and multiorgan involvement: Case report and literature review. J Radiol Case Rep 13(12):1\u201312. https:\/\/doi.org\/10.3941\/jrcr.v13i12.3784","journal-title":"J Radiol Case Rep"},{"issue":"2","key":"7114_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/cyt.12365","volume":"28","author":"ACW Lopes","year":"2017","unstructured":"Lopes ACW, Xavier FD, de Souza Barroso R, Gomes HR, Sales MM (2017) Massive central nervous system infiltration by CD56-positive plasma cells in multiple myeloma. Cytopathology 28(2):172\u2013174. https:\/\/doi.org\/10.1111\/cyt.12365","journal-title":"Cytopathology"},{"issue":"1","key":"7114_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/CJI.0000000000000391","volume":"45","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zu C, Teng X, Yang L, Zhang M et al (2022) BCMA CAR-T Therapy Is Safe and Effective for Refractory\/Relapsed Multiple Myeloma With Central Nervous System Involvement. J Immunother 45(1):25\u201334. https:\/\/doi.org\/10.1097\/CJI.0000000000000391","journal-title":"J Immunother"},{"issue":"2","key":"7114_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1634\/theoncologist.2019-0356","volume":"25","author":"MC Da Via","year":"2020","unstructured":"Da Via MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U et al (2020) CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. Oncologist 25(2):112\u2013118. https:\/\/doi.org\/10.1634\/theoncologist.2019-0356","journal-title":"Oncologist"},{"issue":"8","key":"7114_CR16","doi-asserted-by":"publisher","first-page":"e235725","DOI":"10.1136\/bcr-2020-235725","volume":"13","author":"O Yazdanpanah","year":"2020","unstructured":"Yazdanpanah O, Kaur J, Shafi I, Sarakbi HA (2020) Diplopia as the initial symptom of multiple myeloma in a patient with sarcoidosis. Bmj Case Rep 13(8):e235725. https:\/\/doi.org\/10.1136\/bcr-2020-235725","journal-title":"Bmj Case Rep"},{"issue":"12","key":"7114_CR17","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ajh.26720","volume":"97","author":"A Tiu","year":"2022","unstructured":"Tiu A, Marks J, Aljuaid R, Alzeer A, Dunleavy K (2022) Multiple myeloma with central nervous system relapse presenting as right pupil-sparing complete third nerve palsy. Am J Hematol 97(12):1666\u20131668. https:\/\/doi.org\/10.1002\/ajh.26720","journal-title":"Am J Hematol"},{"issue":"3","key":"7114_CR18","doi-asserted-by":"publisher","first-page":"e239917","DOI":"10.1136\/bcr-2020-239917","volume":"14","author":"T Vaid","year":"2021","unstructured":"Vaid T, Dhawan R, Aggarwal M, Tyagi S (2021) Isolated third cranial nerve palsy as the first presentation of multiple myeloma. Bmj Case Rep 14(3):e239917. https:\/\/doi.org\/10.1136\/bcr-2020-239917","journal-title":"Bmj Case Rep"},{"issue":"6","key":"7114_CR19","doi-asserted-by":"publisher","first-page":"e40998","DOI":"10.7759\/cureus.40998","volume":"15","author":"N Thalambedu","year":"2023","unstructured":"Thalambedu N, Damalcheruvu P, Ogunsesan Y, Patel T, Bachu R et al (2023) Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature. Cureus J Med Sci 15(6):e40998. https:\/\/doi.org\/10.7759\/cureus.40998","journal-title":"Cureus J Med Sci"},{"issue":"1","key":"7114_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3941\/jrcr.v18i1.5240","volume":"18","author":"N Joshi","year":"2024","unstructured":"Joshi N, Li J, Karambelkar A, Boere P (2024) Isolated Abducens Nerve Palsy: A Rare Manifestation of Recurrent Extramedullary Myeloma. J Radiol Case Rep 18(1):14\u201319. https:\/\/doi.org\/10.3941\/jrcr.v18i1.5240","journal-title":"J Radiol Case Rep"},{"issue":"3","key":"7114_CR21","doi-asserted-by":"publisher","first-page":"e156417","DOI":"10.3897\/folmed.67.e156417","volume":"67","author":"A Gozzetti","year":"2025","unstructured":"Gozzetti A (2025) Extramedullary CNS myeloma. Folia Med (Plovdiv) 67(3):e156417. https:\/\/doi.org\/10.3897\/folmed.67.e156417","journal-title":"Folia Med (Plovdiv)"},{"issue":"7","key":"7114_CR22","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","volume":"105","author":"PA Egan","year":"2020","unstructured":"Egan PA, Elder PT, Deighan WI, O Connor SJM, Alexander HD (2020) Multiple myeloma with central nervous system relapse. Haematologica 105(7):1780\u20131790. https:\/\/doi.org\/10.3324\/haematol.2020.248518","journal-title":"Haematologica"},{"issue":"4","key":"7114_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.clml.2024.11.010","volume":"25","author":"GS Manzar","year":"2025","unstructured":"Manzar GS, Dudzinski SO, Yoder AK, Seo A, Nasr LF et al (2025) Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy. Cl Lymph Myelom Leuk 25(4):271\u2013284. https:\/\/doi.org\/10.1016\/j.clml.2024.11.010","journal-title":"Cl Lymph Myelom Leuk"},{"issue":"6","key":"7114_CR24","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/cncr.26447","volume":"118","author":"A Gozzetti","year":"2012","unstructured":"Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A et al (2012) Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer-Am Cancer Soc 118(6):1574\u20131584. https:\/\/doi.org\/10.1002\/cncr.26447","journal-title":"Cancer-Am Cancer Soc"},{"issue":"6","key":"7114_CR25","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.clml.2015.02.028","volume":"15","author":"TU Marron","year":"2015","unstructured":"Marron TU, Ramanathan L, Chari A (2015) Diagnostic utility of measuring free light chains in the cerebrospinal fluid of patients with multiple myeloma. Cl Lymph Myelom Leuk 15(6):e127\u2013e131. https:\/\/doi.org\/10.1016\/j.clml.2015.02.028","journal-title":"Cl Lymph Myelom Leuk"},{"issue":"6","key":"7114_CR26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/bjh.13549","volume":"172","author":"F Marchesi","year":"2016","unstructured":"Marchesi F, Masi S, Summa V, Gumenyuk S, Merola R et al (2016) Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience. Brit J Haematol 172(6):980\u2013982. https:\/\/doi.org\/10.1111\/bjh.13549","journal-title":"Brit J Haematol"},{"issue":"3","key":"7114_CR27","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.21037\/tcr-2024-2157","volume":"14","author":"A Gozzetti","year":"2025","unstructured":"Gozzetti A (2025) Central nervous system and osteodural multiple myeloma. Transl Cancer Res 14(3):2168\u20132169. https:\/\/doi.org\/10.21037\/tcr-2024-2157","journal-title":"Transl Cancer Res"},{"issue":"1","key":"7114_CR28","doi-asserted-by":"publisher","first-page":"104263","DOI":"10.1016\/j.lpm.2024.104263","volume":"54","author":"J Virk","year":"2025","unstructured":"Virk J, Hillengass J (2025) Imaging in multiple myeloma. La Presse M\u00e9dicale 54(1):104263. https:\/\/doi.org\/10.1016\/j.lpm.2024.104263","journal-title":"La Presse M\u00e9dicale"},{"issue":"2020","key":"7114_CR29","doi-asserted-by":"publisher","first-page":"8563098","DOI":"10.1155\/2020\/8563098","volume":"2020","author":"R Bergantim","year":"2020","unstructured":"Bergantim R, Bastos J, Soares MJ, Carvalho B, Soares P et al (2020) Aggressive Central Nervous System Relapse after Autologous Stem Cell Transplant in Multiple Myeloma: Case Reports and Literature Review. Case Rep Hematol 2020(2020):8563098. https:\/\/doi.org\/10.1155\/2020\/8563098","journal-title":"Case Rep Hematol"},{"issue":"1","key":"7114_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12185-023-03545-7","volume":"118","author":"T Obo","year":"2023","unstructured":"Obo T, Morita K, Sumida Y, Nakazaki-Watadani K, Ikemura M et al (2023) Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review. Int J Hematol 118(1):135\u2013140. https:\/\/doi.org\/10.1007\/s12185-023-03545-7","journal-title":"Int J Hematol"},{"issue":"1","key":"7114_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40364-025-00777-z","volume":"13","author":"V Navrkalova","year":"2025","unstructured":"Navrkalova V, Mareckova A, Hricko S, Hrabcakova V, Radova L et al (2025) Reliable detection of CNS lymphoma-derived circulating tumor DNA in cerebrospinal fluid using multi-biomarker NGS profiling: insights from a real-world study. Biomark Res 13(1):71. https:\/\/doi.org\/10.1186\/s40364-025-00777-z","journal-title":"Biomark Res"},{"issue":"4","key":"7114_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bjh.12414","volume":"162","author":"CI Chen","year":"2013","unstructured":"Chen CI, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C et al (2013) Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Brit J Haematol 162(4):483\u2013488. https:\/\/doi.org\/10.1111\/bjh.12414","journal-title":"Brit J Haematol"},{"issue":"1","key":"7114_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bjhh.2017.09.004","volume":"40","author":"ALMS Dias","year":"2018","unstructured":"Dias ALMS, Higashi F, Peres ALM, Cury P, Crusoe EDQ et al (2018) Multiple myeloma and central nervous system involvement: experience of a Brazilian center. Hematol Transf Cell 40(1):30\u201336. https:\/\/doi.org\/10.1016\/j.bjhh.2017.09.004","journal-title":"Hematol Transf Cell"},{"key":"7114_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.25259\/SNI_693_2020","volume":"12","author":"K Onodera","year":"2021","unstructured":"Onodera K, Kurisu K, Takebayashi S, Sakurai J, Kobayashi T et al (2021) Intracranial plasmacytoma arising from dura mater secondary to multiple myeloma and presenting with sudden lethal intracerebral hemorrhage: A case report and literature review. Surg Neurol Int 12:55. https:\/\/doi.org\/10.25259\/SNI_693_2020","journal-title":"Surg Neurol Int"},{"issue":"11","key":"7114_CR35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.clml.2016.08.010","volume":"16","author":"J Paludo","year":"2016","unstructured":"Paludo J, Painuly U, Kumar S, Gonsalves WI, Rajkumar V et al (2016) Myelomatous Involvement of the Central Nervous System. Cl Lymph Myelom Leuk 16(11):644\u2013654. https:\/\/doi.org\/10.1016\/j.clml.2016.08.010","journal-title":"Cl Lymph Myelom Leuk"},{"key":"7114_CR36","doi-asserted-by":"publisher","first-page":"100207","DOI":"10.1016\/j.lrr.2020.100207","volume":"14","author":"A Mittal","year":"2020","unstructured":"Mittal A, Pushpam D, Kumar L (2020) Isolated central nervous system relapse of multiple myeloma post autologous stem cell transplant- A rare presentation. Leuk Res Rep 14:100207. https:\/\/doi.org\/10.1016\/j.lrr.2020.100207","journal-title":"Leuk Res Rep"},{"key":"7114_CR37","doi-asserted-by":"publisher","first-page":"100210","DOI":"10.1016\/j.lrr.2020.100210","volume":"14","author":"K Mousavi-Fatemi","year":"2020","unstructured":"Mousavi-Fatemi K, Maleki N (2020) Management of central nervous system involvement in multiple myeloma after autologous hematopoietic stem cell transplantation. Leuk Res Rep 14:100210. https:\/\/doi.org\/10.1016\/j.lrr.2020.100210","journal-title":"Leuk Res Rep"},{"key":"7114_CR38","doi-asserted-by":"publisher","first-page":"1027585","DOI":"10.3389\/fonc.2022.1027585","volume":"12","author":"X Li","year":"2022","unstructured":"Li X, Wang W, Zhang X, Liang Y (2022) Multiple myeloma with isolated central nervous system relapse after autologous stem cell transplantation: A case report and review of the literature. Front Oncol 12:1027585. https:\/\/doi.org\/10.3389\/fonc.2022.1027585","journal-title":"Front Oncol"},{"issue":"3","key":"7114_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2169\/internalmedicine.5646-20","volume":"60","author":"M Hotta","year":"2021","unstructured":"Hotta M, Ito T, Konishi A, Yoshimura H, Nakanishi T et al (2021) Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review. Intern Med 60(3):463\u2013468. https:\/\/doi.org\/10.2169\/internalmedicine.5646-20","journal-title":"Intern Med"},{"key":"7114_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.21037\/acr-24-19","volume":"8","author":"EE Reynoso-Gomez","year":"2024","unstructured":"Reynoso-Gomez EE, Quintero-Hernandez CE (2024) Isolated central nervous system (CNS) relapse of multiple myeloma 11 years after autologous stem cell transplantation: a case report. Ame Case Rep 8:111. https:\/\/doi.org\/10.21037\/acr-24-19","journal-title":"Ame Case Rep"},{"issue":"7","key":"7114_CR41","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","volume":"21","author":"N Shah","year":"2015","unstructured":"Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, American Society for Blood and Marrow Transplantation et al (2015) Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl 21(7):1155\u20131166. https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.002","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"7114_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/hon.2208","volume":"34","author":"J Lee","year":"2016","unstructured":"Lee J, Smith D, Rabin N, Tobias J, Yong K (2016) 17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management. Hematol Oncol 34(3):165\u2013170. https:\/\/doi.org\/10.1002\/hon.2208","journal-title":"Hematol Oncol"},{"issue":"7","key":"7114_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/15384047.2016.1178427","volume":"17","author":"MB Abid","year":"2016","unstructured":"Abid MB, De Mel S, Abid MA, Tan KB, Chng WJ (2016) Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence. Cancer Biol Ther 17(7):723\u2013726. https:\/\/doi.org\/10.1080\/15384047.2016.1178427","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"7114_CR44","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/neuonc\/nov299","volume":"18","author":"K Di","year":"2016","unstructured":"Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ et al (2016) Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neurooncology 18(6):840\u2013848. https:\/\/doi.org\/10.1093\/neuonc\/nov299","journal-title":"Neurooncology"},{"issue":"2","key":"7114_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/bjh.14498","volume":"177","author":"A Badros","year":"2017","unstructured":"Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A et al (2017) Marizomib for central nervous system-multiple myeloma. Brit J Haematol 177(2):221\u2013225. https:\/\/doi.org\/10.1111\/bjh.14498","journal-title":"Brit J Haematol"},{"issue":"1","key":"7114_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/jcpt.13054","volume":"45","author":"S Oka","year":"2020","unstructured":"Oka S, Ono K, Nohgawa M (2020) Successful treatment with pomalidomide and intrathecal injections for central nervous system plasmacytoma in a patient under haemodialysis. J Clin Pharm Ther 45(1):221\u2013225. https:\/\/doi.org\/10.1111\/jcpt.13054","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"7114_CR47","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3109\/10428194.2012.718343","volume":"54","author":"A Mussetti","year":"2013","unstructured":"Mussetti A, Dalto S, Montefusco V (2013) Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymphoma 54(4):864\u2013866. https:\/\/doi.org\/10.3109\/10428194.2012.718343","journal-title":"Leuk Lymphoma"},{"key":"7114_CR48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.reth.2022.05.007","volume":"21","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zu C, Ni F, Yang Z, Zhang Z et al (2022) Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement. Regen Ther 21:34\u201336. https:\/\/doi.org\/10.1016\/j.reth.2022.05.007","journal-title":"Regen Ther"},{"issue":"12","key":"7114_CR49","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s00277-015-2484-y","volume":"94","author":"E Katodritou","year":"2015","unstructured":"Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS et al (2015) Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Ann Hematol 94(12):2033\u20132042. https:\/\/doi.org\/10.1007\/s00277-015-2484-y","journal-title":"Ann Hematol"},{"issue":"3","key":"7114_CR50","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00277-015-2586-6","volume":"95","author":"A Gozzetti","year":"2016","unstructured":"Gozzetti A, Cerase A, Bocchia M (2016) Central nervous system multiple myeloma. Ann Hematol 95(3):519\u2013520. https:\/\/doi.org\/10.1007\/s00277-015-2586-6","journal-title":"Ann Hematol"},{"key":"7114_CR51","doi-asserted-by":"publisher","first-page":"4081971","DOI":"10.1155\/2022\/4081971","volume":"2022","author":"JW Kuan","year":"2022","unstructured":"Kuan JW, Chai SL, Rajadurai P, Lau LG, Uchang J et al (2022) A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone. Case Rep Hematol 2022:4081971. https:\/\/doi.org\/10.1155\/2022\/4081971","journal-title":"Case Rep Hematol"},{"issue":"4","key":"7114_CR52","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/10428194.2012.723708","volume":"54","author":"MA Gertz","year":"2013","unstructured":"Gertz MA (2013) Pomalidomide and myeloma meningitis. Leuk Lymphoma 54(4):681\u2013682. https:\/\/doi.org\/10.3109\/10428194.2012.723708","journal-title":"Leuk Lymphoma"},{"key":"7114_CR53","doi-asserted-by":"publisher","first-page":"1276295","DOI":"10.3389\/fimmu.2023.1276295","volume":"14","author":"YG Mutlu","year":"2023","unstructured":"Mutlu YG, Yigit Kaya S, Maral S, Melek E, Baslar Z et al (2023) Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. Front Immunol 14:1276295. https:\/\/doi.org\/10.3389\/fimmu.2023.1276295","journal-title":"Front Immunol"},{"issue":"1","key":"7114_CR54","doi-asserted-by":"publisher","first-page":"8425047","DOI":"10.1155\/crh\/8425047","volume":"2025","author":"J Blackman","year":"2025","unstructured":"Blackman J, Blackman JT, Pauranik A, Freeman AT (2025) A Case Report Supporting the Use of Teclistamab in Multiple Myeloma With CNS Involvement. Case Rep Hematol 2025(1):8425047. https:\/\/doi.org\/10.1155\/crh\/8425047","journal-title":"Case Rep Hematol"},{"issue":"S1","key":"7114_CR55","first-page":"1644","volume":"8","author":"F Lachenal","year":"2024","unstructured":"Lachenal F, Gerome T, Chalopin T, Uribe MO, Tabrizi R et al (2024) Effectiveness and safety of bispecific antibodies targeting BCMA and CD3 in patients with central nervous system multiple myeloma (CNS-MM): IFM 2023-06, a retrospective cohort study. Hemasphere 8(S1):1644\u20131645","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"7114_CR56","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1182\/blood-2025-824","volume":"146","author":"M Gaballa","year":"2025","unstructured":"Gaballa M, Feng L, Afrough A, Banerjee R, Davis J et al (2025) Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement. Blood 146(Supplement 1):824. https:\/\/doi.org\/10.1182\/blood-2025-824","journal-title":"Blood"},{"issue":"S1","key":"7114_CR57","first-page":"3686","volume":"8","author":"J Mersi","year":"2024","unstructured":"Mersi J, Eisele F, Zhou X, Heidemeier A, Stanojkovska E et al (2024) The role of bispecific antibodies and CAR T cells in the treatment of multiple myeloma with central nervous system involvement. Hemasphere 8(S1):3686\u20133687","journal-title":"Hemasphere"},{"key":"7114_CR58","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/S2152-2650(25)03560-8","volume":"25","author":"W Tian","year":"2025","unstructured":"Tian W, Li L (2025) Efficacy and Safety of CAR-T Therapy in CNS-MM. Clinical Lymphoma. Myeloma Leuk 25:S101. https:\/\/doi.org\/10.1016\/S2152-2650(25)03560-8","journal-title":"Myeloma Leuk"},{"issue":"8","key":"7114_CR59","doi-asserted-by":"publisher","first-page":"e70192","DOI":"10.1002\/hem3.70192","volume":"9","author":"M Maulhardt","year":"2025","unstructured":"Maulhardt M, Call S, Boyadzhiev H, Albici AM, Horster K et al (2025) Efficacy of idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis. Hemasphere 9(8):e70192. https:\/\/doi.org\/10.1002\/hem3.70192","journal-title":"Hemasphere"},{"key":"7114_CR60","doi-asserted-by":"publisher","first-page":"755584","DOI":"10.3389\/fonc.2021.755584","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang L, Zeng Y, Hong R, Zu C et al (2021) Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome-A Wandering Road to Remission. Front Oncol 11:755584. https:\/\/doi.org\/10.3389\/fonc.2021.755584","journal-title":"Front Oncol"},{"key":"7114_CR61","doi-asserted-by":"publisher","first-page":"854448","DOI":"10.3389\/fonc.2022.854448","volume":"12","author":"T Wang","year":"2022","unstructured":"Wang T, He T, Ma L, Yang Y, Feng R et al (2022) Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion. Front Oncol 12:854448. https:\/\/doi.org\/10.3389\/fonc.2022.854448","journal-title":"Front Oncol"},{"issue":"1","key":"7114_CR62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/j.seminhematol.2025.02.001","volume":"62","author":"L Sanchez","year":"2025","unstructured":"Sanchez L, Richard S (2025) Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies. Semin Hematol 62(1):31\u201337. https:\/\/doi.org\/10.1053\/j.seminhematol.2025.02.001","journal-title":"Semin Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07114-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07114-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07114-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:43:09Z","timestamp":1789465389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07114-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7114"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07114-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"377"}}